Table 2.

Pan-AKT inhibitors in clinical development

Drug	Mechanism	Tumour types	Phase	Study design/combination Partner	Cliniclatrials.gov Number
Ipatasertib (GDC-0068)	ATP-competitive pan-AKT inhibitor	Breast	Ib	Trastuzumab/pertuzumab	NCT04253561
		Breast/ovary/prostate	Ib	Rucaparib	NCT03840200
		Breast	I/Ib	Carboplatin or carboplatin/paclitaxel	NCT03853707
		Solid tumours	I	Atezolizumab	NCT03673787
		Brain tumour	IIb	Pembrolizumab	NCT02430363
		Breast	Ib	Atezolizumb/paclitaxel	NCT03800836
				Atezolizumab/Nab-paclitaxel
		Breast	Ib	Aromatase inhibitors or fulvestrant or fulvestrant/palbociclib	NCT03959891
		Prostate	Ib/II	Abiraterone or abiraterone/apitolisib	NCT01485861
		Breast	II	Atezolizumab or atezolizumab/bevacizumab	NCT03395899
		Breast	III	Paclitaxel	NCT03337724
		Breast	III	Atezolizumab/paclitaxel	NCT04177108
		Prostate	III	Abiraterone/prednisolone	NCT03072238
Capivasertib (AZD5363)	ATP-competitive pan-AKT inhibitor	Solid tumours	I	Olaparib	NCT02338622
		Solid tumours	I	Olaparib/durvalumab	NCT03772561
		Breast/ovary/endometrium	Ib	Olaparib	NCT02208375
		Prostate	I	Enzalutamide or abiraterone	NCT04087174
		Prostate	II	Enazalutamide	NCT02525068
		Breast	III	Paclitaxel	NCT03997123
Afuresertib (GSK2110183)	ATP-competitive pan-AKT inhibitor	Prostate	I/II	LAE001/prednisolone	NCT04060394
		Stomach	Ib*	Paclitaxel	NCT02240212
Uprosertib (GSK2141795)	ATP-competitive pan-AKT inhibitor	Multiple myeloma	II*	Trametinib	NCT01989598
Miransertib (ARQ 092)	Allosteric pan-AKT and AKT1 E17K inhibitor	Ovary	Ib*	Paclitaxel or paclitaxel/carboplatin or anastrozole	NCT02476955

Biomarker-driven studies have been excluded from this list.

*Clinicaltrials.gov has noted no active patient enrolment in this study.